Cochrane · systematic review · CD009864
Topical tacrolimus for atopic dermatitis
Cury Martins, J, Martins, C, Aoki, V, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
23
current version
GRADE rated
23
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 13%Low 8 · 34.8%Moderate 10 · 43.5%High 2 · 8.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Tacrolimus 0.1% compared with corticosteroids for atopic dermatitis
Population: people with atopic dermatitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks Tacrolimus 0.1% vs corticosteroids | RR 3.09 [2.14, 4.45] | 1 study · 371 participants | Moderate Downgraded: imprecision, publication bias |
Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks Tacrolimus 0.1% vs corticosteroids | RR 0.95 [0.78, 1.16] | 1 study · 377 participants | Low Downgraded: imprecision, publication bias |
Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: short term (6 months) Tacrolimus 0.1% vs corticosteroids | RR 1.32 [1.17, 1.49] | 1 study · 972 participants | Moderate Downgraded: imprecision, publication bias |
Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks Tacrolimus 0.1% vs corticosteroids | RR 2.91 [1.6, 5.28] | 1 study · 371 participants | Moderate Downgraded: imprecision, publication bias |
Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks Tacrolimus 0.1% vs corticosteroids | RR 4.59 [3.1, 6.78] | 1 study · 377 participants | Moderate Downgraded: imprecision, publication bias |
Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: 6 months Tacrolimus 0.1% vs corticosteroids | RR 3.79 [2.99, 4.81] | 1 study · 972 participants | Moderate Downgraded: imprecision, publication bias |
Participant's self‐assessment of global response of improvement Tacrolimus 0.1% vs corticosteroids | RR 1.21 [1.13, 1.29] | 1 study · 974 participants | Low Downgraded: imprecision, publication bias |
Tacrolimus 0.1% compared with pimecrolimus 1% for atopic dermatitis
Population: people with atopic dermatitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks Tacrolimus 0.1% vs pimecrolimus 1% | RR 1.8 [1.34, 2.42] | 2 studies · 506 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Adverse effects ‐ 6 weeks Tacrolimus 0.1% vs pimecrolimus 1% | RR 0.89 [0.47, 1.71] | 2 studies · 506 participants | Very low Downgraded: imprecision, inconsistency, publication bias |
Tacrolimus 0.03% compared with corticosteroids for atopic dermatitis
Population: people with atopic dermatitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 1x/day versus hydrocortisone acetate 1% 2x/day Tacrolimus 0.03% vs corticosteroids | RR 2.05 [1.36, 3.08] | 1 study · 411 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day Tacrolimus 0.03% vs corticosteroids | RR 2.58 [1.96, 3.38] | 2 studies · 790 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 2x/day versus corticosteroids moderate‐potency 2x/day Tacrolimus 0.03% vs corticosteroids | RR 0.45 [0.13, 1.57] | 2 studies · 409 participants | Very low Downgraded: imprecision, inconsistency, publication bias |
Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.03% 2x/day versus methylprednisolone 0.03% 1x/day Tacrolimus 0.03% vs corticosteroids | RR 1 [0.85, 1.19] | 1 study · 265 participants | Low Downgraded: imprecision, inconsistency, publication bias |
Adverse effects: burning ‐ tacrolimus 0.03% versus steroids Tacrolimus 0.03% vs corticosteroids | 2.48 [1.96, 3.14] | 5 studies · 1883 participants | High |
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day Tacrolimus 0.03% vs corticosteroids | RR 1.64 [1.41, 1.9] | 1 study · 416 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Tacrolimus 0.03% compared with tacrolimus 0.1% for atopic dermatitis
Population: people with atopic dermatitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Physician's assessment of global response of improvement, clear or excellent Tacrolimus 0.03% vs tacrolimus 0.1% | RR 0.82 [0.72, 0.92] | 6 studies · 1640 participants | High |
Adverse effects Tacrolimus 0.03% vs tacrolimus 0.1% | RR 0.95 [0.86, 1.06] | 4 studies · 986 participants | Moderate Downgraded: imprecision |
Tacrolimus 0.03% versus pimecrolimus 1% for atopic dermatitis
Population: people with atopic dermatitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Physician's assessment of global response of improvement Tacrolimus 0.03% vs pimecrolimus 1% | RR 1.42 [1.02, 1.98] | 1 study · 139 participants | Low Downgraded: imprecision, publication bias |
Adverse effects ‐ application site reaction Tacrolimus 0.03% vs pimecrolimus 1% | RR 1.07 [0.6, 1.91] | 1 study · 141 participants | Low Downgraded: imprecision, publication bias |
Adverse effects ‐ burning Tacrolimus 0.03% vs pimecrolimus 1% | RR 0.87 [0.43, 1.75] | 1 study · 141 participants | Low Downgraded: imprecision, publication bias |
Adverse effects ‐ itching Tacrolimus 0.03% vs pimecrolimus 1% | RR 2.37 [0.96, 5.81] | 1 study · 141 participants | Low Downgraded: imprecision, publication bias |
Adverse effects ‐ erythema Tacrolimus 0.03% vs pimecrolimus 1% | RR 2.2 [0.89, 5.46] | 1 study · 141 participants | Low Downgraded: imprecision, publication bias |
Tacrolimus 0.1% versus ciclosporin for atopic dermatitis
Population: people with atopic dermatitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adverse effects Tacrolimus 0.1% vs ciclosporin | RR 1 [0.31, 3.28] | 1 study · 30 participants | Very low Downgraded: risk of bias, imprecision, publication bias |